Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.
Roy S. Herbst,Edward B. Garon,Dong Wan Kim,Byoung Chul Cho,Jose Luis Perez-Gracia,Ji Youn Han,Catherine Dubos Arvis,Margarita Majem,Martin Forster,Isabelle Monnet,Silvia Novello,Zsuzsanna Szalai,Matthew A. Gubens,Wu Chou Su,Giovanni Luca Ceresoli,A. Samkari,Erin Jensen,Gregory M. Lubiniecki,Paul Baas +18 more
Reads0
Chats0
TLDR
Pembrolizumab provided long-term OS benefit over docetaxel, with manageable safety, durable responses among patients receiving 2 years of treatment, and disease control with second-course treatment, further supporting pembrolIZumab for previously treated, PD-L1‒expressing advanced NSCLC.Abstract:
PURPOSEIn the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in previously treated, programmed death-ligand 1 (PD-L1)‒expressing advanced non‒small-cell lung cance...read more
Citations
More filters
Journal ArticleDOI
Acquired Resistance to Immune Checkpoint Inhibitors.
TL;DR: The barriers to progress and emerging clinical reports interrogating acquired resistance are examined with the goal to facilitate efforts to overcome acquired resistance to ICIs in the future.
Journal ArticleDOI
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50%
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Ticiana A. Leal,Jonathan W. Riess,Erin Jensen,Bin Zhao,M. Catherine Pietanza,Julie R. Brahmer +18 more
TL;DR: The first 5-year follow-up of any first-line phase III immunotherapy trial for non-small-cell lung cancer (NSCLC) was reported in this article.
Journal ArticleDOI
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
TL;DR: In this article , the authors reported that the addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery.
Journal ArticleDOI
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
Delvys Rodriguez-Abreu,Steven Francis Powell,Maximilian Hochmair,Shirish M. Gadgeel,Emilio Esteban,Enriqueta Felip,G. Speranza,F. De Angelis,Manuel Domine,S. Cheng,Helge Bischoff,N. Peled,Martin Reck,Rina Hui,Edward B. Garon,Michael Boyer,Takayasu Kurata,J. Yang,M.C. Pietanza,Fabricio Souza,M.C. Garassino +20 more
TL;DR: Pembrolizumab plus pemetrexed and platinum-based chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) as discussed by the authors.
Journal ArticleDOI
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.
TL;DR: In this paper, the authors provide guidance on selecting the optimal ICI-based therapy and highlight several future research directions that will probably further improve the outcomes of patients with advanced-stage non-small-cell lung cancer.
References
More filters
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Julien Mazieres,Alexander Drilon,Amélie Lusque,Laurent Mhanna,Alexis B. Cortot,Laura Mezquita,A. Thai,C. Mascaux,Sébastien Couraud,Remi Veillon,M. van den Heuvel,Joel W. Neal,Nir Peled,Martin Früh,Terry L. Ng,Valérie Gounant,Sanjay Popat,Joachim Diebold,Joshua K. Sabari,Viola W. Zhu,Sacha I. Rothschild,Paolo Bironzo,Alex Martinez-Marti,Alessandra Curioni-Fontecedro,Rafael Rosell,Mickaël Lattuca-Truc,Marcel Wiesweg,Benjamin Besse,Benjamin Solomon,Fabrice Barlesi,R.D. Schouten,Heather A. Wakelee,D.R. Camidge,Gérard Zalcman,Silvia Novello,S-H.I. Ou,Julie Milia,Oliver Gautschi +37 more
TL;DR: In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2) and the lack of response in the ALK group was notable.
Journal ArticleDOI
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
Everett E. Vokes,Neal Ready,Enriqueta Felip,Leora Horn,Marco Angelo Burgio,S.J. Antonia,O. Aren Frontera,Scott N. Gettinger,Esther Holgado,David R. Spigel,David M. Waterhouse,Manuel Domine,Marina Chiara Garassino,Laura Q.M. Chow,George R. Blumenschein,Fabrice Barlesi,Bruno Coudert,Justin F. Gainor,Oscar Arrieta,Julie R. Brahmer,Charles Butts,Martin Steins,William J. Geese,Ang Li,Diane Healey,L. Crinò +25 more
TL;DR: In this article, the anti-programmed death-1 antibody nivolumab versus docetaxel was compared in patients with previously treated advanced squamous (CheckMate 017) and nonsquamous NSCLC.
Journal ArticleDOI
Evaluation of dosing strategy for pembrolizumab for oncology indications
Tomoko Freshwater,Anna Georgieva Kondic,Malidi Ahamadi,Claire Li,Rik de Greef,Dinesh P. de Alwis,Julie A. Stone +6 more
TL;DR: It is suggested that weight-based and fixed-dose regimens are appropriate for pembrolizumab and high-weight patients had the lowest exposures with 200 mg Q3W; however, exposures in this group (>90 kg) were within the range of prior clinical experience at 2 mg/kgQ3W associated with near maximal efficacy.
Journal ArticleDOI
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
TL;DR: The role of pembrolizumab in the treatment of advanced (recurrent/metastatic) NSCLC is provided, and agents that interfere with the programmed death 1 (PD-1) pathway, which many tumors can hijack to avoid immune surveillance and editing are explored.
Related Papers (5)
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi,Delvys Rodriguez-Abreu,Shirish M. Gadgeel,Emilio Esteban,Enriqueta Felip,Flávia De Angelis,Manuel Domine,Philip Clingan,Maximilian J. Hochmair,Steven Francis Powell,Susanna Y.-S. Cheng,Helge Bischoff,Nir Peled,Francesco Grossi,Ross Jennens,Martin Reck,Rina Hui,Edward B. Garon,Michael Boyer,Belén Rubio-Viqueira,Silvia Novello,Takayasu Kurata,Jhanelle E. Gray,John Vida,Ziwen Wei,J. Yang,Harry Raftopoulos,M. Catherine Pietanza,Marina Chiara Garassino +28 more
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer,Fabrice Barlesi,Daniel Waterkamp,Keunchil Park,Fortunato Ciardiello,Joachim von Pawel,Shirish M. Gadgeel,Toyoaki Hida,Dariusz M. Kowalski,Manuel Cobo Dols,Diego Cortinovis,Joseph W. Leach,Jonathan Polikoff,Carlos H. Barrios,Fairooz F. Kabbinavar,Osvaldo Arén Frontera,Filippo de Marinis,Hande Turna,Jong Seok Lee,Marcus Ballinger,Marcin Kowanetz,Pei He,Daniel S. Chen,Alan Sandler,David R. Gandara +24 more